Emergent BioSolutions reported Q2 2024 revenues of $254.7 million, down 25% YoY, with a net loss of $283.1 million. NARCAN Nasal Spray sales declined 10% to $120 million, while Anthrax MCM revenues increased 83% to $38.7 million. The quarter included a $110.2 million settlement charge related to Janssen contract dispute resolution.The company made significant progress in debt reduction through strategic asset sales, including $75 million from RSDL sale to SERB, $30 million pending from Baltimore-Camden facility sale to Bora, and $50 million received from Janssen settlement. Additionally, secured $250 million in U.S. government contract modifications for four medical countermeasures.Management updated FY2024 guidance, raising revenue forecast to $1.05-1.125 billion and adjusted EBITDA to $140-180 million. The company expects to exceed $200 million in debt reduction by year-end, while continuing to focus on streamlining operations and strengthening its core public health preparedness business.

Emergent BioSolutions reported Q2 2024 revenues of $254.7 million, down 25% YoY, with a net loss of $283.1 million. NARCAN Nasal Spray sales declined 10% to $120 million, while Anthrax MCM revenues increased 83% to $38.7 million. The quarter included a $110.2 million settlement charge related to Janssen contract dispute resolution.The company made significant progress in debt reduction through strategic asset sales, including $75 million from RSDL sale to SERB, $30 million pending from Baltimore-Camden facility sale to Bora, and $50 million received from Janssen settlement. Additionally, secured $250 million in U.S. government contract modifications for four medical countermeasures.Management updated FY2024 guidance, raising revenue forecast to $1.05-1.125 billion and adjusted EBITDA to $140-180 million. The company expects to exceed $200 million in debt reduction by year-end, while continuing to focus on streamlining operations and strengthening its core public health preparedness business.